Anlon Healthcare Limited Stock Price Today (NSE: AHCL)
Fundamental Score
Anlon Healthcare Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Anlon Healthcare Limited share price today is ₹20.04, down 0.69% on NSE/BSE as of 16 September 2026. Anlon Healthcare Limited (AHCL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.07K (Cr). The 52-week high for AHCL share price is ₹22.94 and the 52-week low is ₹10.37. At a P/E ratio of 3.43x, AHCL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 19.17% and a debt-to-equity ratio of 0.19.
Anlon Healthcare Limited Share Price Chart — NSE/BSE Historical Performance
Anlon Healthcare Limited share price chart: 12.66% return over the past month. 52-week high ₹22.94, 52-week low ₹10.37.
Anlon Healthcare Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹20.20 | ₹20.50 | ₹19.60 | ₹20.04 | 460.66L (Cr) | |
| ₹21.05 | ₹22.94 | ₹19.37 | ₹20.18 | 1650.56L (Cr) | |
| ₹17.73 | ₹20.00 | ₹17.54 | ₹19.57 | 1507.49L (Cr) | |
| ₹16.41 | ₹18.00 | ₹16.05 | ₹17.54 | 316.30L (Cr) | |
| ₹15.62 | ₹16.68 | ₹15.62 | ₹16.28 | 174.59L (Cr) | |
| ₹15.54 | ₹15.69 | ₹15.41 | ₹15.61 | 14.55L (Cr) | |
| ₹15.74 | ₹15.85 | ₹15.41 | ₹15.51 | 21.77L (Cr) | |
| ₹15.68 | ₹15.89 | ₹15.54 | ₹15.68 | 20.50L (Cr) | |
| ₹15.47 | ₹16.25 | ₹15.47 | ₹15.60 | 51.13L (Cr) | |
| ₹15.49 | ₹15.76 | ₹15.32 | ₹15.56 | 16.68L (Cr) |
Anlon Healthcare Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹15.93 | ₹22.94 | ₹15.32 | ₹20.04 | +25.80% | |
| ₹14.45 | ₹16.87 | ₹13.81 | ₹15.86 | +9.76% | |
| ₹16.00 | ₹16.45 | ₹14.18 | ₹14.61 | -8.69% | |
| ₹13.98 | ₹16.78 | ₹13.45 | ₹15.99 | +14.38% | |
| ₹13.30 | ₹15.02 | ₹12.99 | ₹13.85 | +4.14% | |
| ₹11.49 | ₹17.20 | ₹11.10 | ₹13.30 | +15.71% | |
| ₹10.67 | ₹13.30 | ₹10.37 | ₹11.14 | +4.40% | |
| ₹12.10 | ₹13.20 | ₹10.63 | ₹10.85 | -10.31% | |
| ₹15.18 | ₹16.10 | ₹12.15 | ₹12.24 | -19.37% | |
| ₹17.00 | ₹17.24 | ₹13.30 | ₹15.10 | -11.18% | |
| ₹12.80 | ₹17.27 | ₹12.80 | ₹16.86 | +31.73% | |
| ₹13.35 | ₹13.45 | ₹11.91 | ₹12.86 | -3.66% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Anlon Healthcare Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anlon Healthcare Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AHCL across key market metrics for learning purposes.
Positive Indicators
13 factors identified
Strong Return on Equity (19.17%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.38%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (21.10%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 3.43 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (162.97%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (61.67% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (21.19% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (36.40% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.19)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.36x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.87)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (52.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-97.24 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.92%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Anlon Healthcare Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Anlon Healthcare Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Anlon Healthcare LimitedAnlon Healthcar...Selected✓ AHCL • 544497 | 60.3/100 | ₹20.04₹20 | ₹1065.16₹1065.16 | 3.43Average 3.4 Average | 19.17%Good 19.17% Good | 22.38%Excellent 22.38% Excellent | 0.19Excellent 0.2 Excellent | 36.40%Excellent 36.40% Excellent | 61.67%Excellent 61.67% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Anlon Healthcare Limited Quarterly Performance
Latest quarterly metrics for AHCL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
162.97%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-100.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
61.67%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
36.40%
Compounded annual net profit growth over 5 years
Anlon Healthcare Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AHCL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Anlon Healthcare Limited Financial Statements
Annual income statement, balance sheet and cash flow for Anlon Healthcare Limited (AHCL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Anlon Healthcare Limited
About AHCL (Anlon Healthcare Limited)
Anlon Healthcare is a multifaceted pharmaceutical entity, dedicated to the synthesis and distribution of sophisticated pharmaceutical components across the globe. The company speci...alizes in crafting meticulously engineered intermediates, the crucial building blocks that underpin the creation of final drug formulations. These components are designed to meet the rigorous demands of modern pharmaceutical manufacturing, ensuring both efficacy and safety in the end products. Anlon Healthcare operates with a commitment to precision and innovation, constantly seeking to improve its processes and product offerings to stay at the forefront of the ever-evolving pharmaceutical landscape. Their commitment to quality extends to all stages of their operations, from research and development to manufacturing and distribution. The company's expansive portfolio encompasses a wide array of specialized pharmaceutical ingredients, catering to diverse therapeutic areas. Anlon Healthcare produces active pharmaceutical ingredients (APIs), the very core of medicinal action, as well as nutraceutical APIs for health and wellness applications. They also develop ingredients tailored for personal care products, contributing to advancements in skincare and cosmetic formulations. Further extending their reach, Anlon Healthcare provides veterinary APIs, ensuring the health and well-being of animals. This diversity reflects the company's ability to adapt and innovate, meeting the varying needs of both human and animal healthcare sectors with tailored solutions. By serving various sectors, Anlon is contributing to innovation of healthcare. Anlon Healthcare's products serve as essential components in numerous therapeutic categories, contributing to advancements in treatment and management. These include drugs used in addressing inflammation, pain relief, and fever reduction, as well as antihistamines, antidepressants, and antipsychotics for mental health applications. Their ingredients are also vital in the production of anticoagulants, antihypertensives, and medications for managing conditions such as arrhythmia, hyperparathyroidism, and diabetes. By consistently producing high-quality intermediates and APIs, Anlon Healthcare contributes to the continuous development of novel therapeutic solutions and the improvement of patient outcomes globally. By focusing on innovation, Anlon is constantly adapting to the change in pharmaceutical needs.
Company Details
Key Leadership
AHCL Share Price: Frequently Asked Questions
What is the current share price of Anlon Healthcare Limited?
Anlon Healthcare Limited (AHCL) trades at ₹20.04 on NSE and BSE. Market cap ₹1.07K (Cr). Educational data only.
What is the P/E ratio of Anlon Healthcare Limited?
Anlon Healthcare Limited has a P/E of 3.43x vs industry average 34.89x.
What is the Bull Run score for Anlon Healthcare Limited?
Anlon Healthcare Limited has a Bull Run score of 60.3/100 based on 25+ financial parameters.
Does Anlon Healthcare Limited pay dividends?
Anlon Healthcare Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Anlon Healthcare Limited?
Anlon Healthcare Limited has ROE of 19.17%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Anlon Healthcare Limited?
Anlon Healthcare Limited has debt-to-equity of 0.19.
Is Anlon Healthcare Limited a good investment?
Bull Run gives Anlon Healthcare Limited a score of 60.3/100. This is not investment advice — consult a SEBI-registered advisor.